Zymeworks Common Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Zymeworks Common Stock Summary

Zymeworks Common competes with Day One, Inozyme Pharma, Zentalis Pharmaceuticals, Syndax Pharmaceuticals, and Protagonist Therapeutics. Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people.

Zymeworks Common Key Financial Ratios

Zymeworks Common Key Balance Sheet Accounts

Zymeworks Common Key Income Statement Accounts

Zymeworks Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Zymeworks Common's current stock value. Our valuation model uses many indicators to compare Zymeworks Common value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zymeworks Common competition to find correlations between indicators driving Zymeworks Common's intrinsic value. More Info.Zymeworks Common Stock is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Zymeworks Common's Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zymeworks Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Zymeworks Common Stock Systematic Risk

Today, most investors in Zymeworks Common Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zymeworks Common's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Zymeworks Common growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Zymeworks Common help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zymeworks Common Stock. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zymeworks Common Stock based on widely used predictive technical indicators. In general, we focus on analyzing Zymeworks Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zymeworks Common's daily price indicators and compare them against related drivers.

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.